Safety of live-attenuated measles-mumps-rubella and herpes zoster vaccination in multiple myeloma patients on maintenance lenalidomide or bortezomib after autologous hematopoietic cell transplantation
Alisha Pandit(Brigham and Women's Hospital), Nicolas C. Issa(Dana-Farber Cancer Institute), Sarah P. Hammond(Dana-Farber Cancer Institute), Paul G. Richardson(Harvard University), Francisco M. Marty(Brigham and Women's Hospital), Jacob P. Laubach(Harvard University), Houry Leblebjian(Dana-Farber Cancer Institute), Lindsey R. Baden(Brigham and Women's Hospital)
Cited by 37
Related Papers
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
|New England Journal of Medicine|2003|2.6k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
|New England Journal of Medicine|2020|1.4k
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
|Science|2022|1.2k
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
|New England Journal of Medicine|2017|1.2k